CODX Investor Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Co-Diagnostics, Inc. and Encourages Investors to Contact the Firm

NEW YORK, June 17, 2020 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Co-Diagnostics, Inc. ("Co-Diagnostics" or the "Company") (NASDAQ: CODX). Investors who purchased Co-Diagnostics securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/codx.                        

The investigation concerns whether Co-Diagnostics and certain of its officers and/or directors have violated federal securities laws.

Specifically, the investigation focuses on Co-Diagnostics' statements and whether its COVID-19 testing results were falsified and/or misleading.

If you are aware of any facts relating to this investigation, or purchased Co-Diagnostics shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/codx. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration.   Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | [email protected]

SOURCE Bronstein, Gewirtz & Grossman, LLC

Related Links

https://www.bgandg.com/

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED